Literature DB >> 21155917

Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression.

Farzin Imani1, Fernando E Boada, Frank S Lieberman, Denise K Davis, Erin L Deeb, James M Mountz.   

Abstract

OBJECTIVES: We investigated the accuracy of high-field proton magnetic resonance spectroscopy ((1) H MRS) and fluorine-18 2-fluoro-deoxyglucose positron emission tomography ((18) F-FDG-PET) for diagnosis of glioma progression following tumor resection, stereotactic radiation, and chemotherapy.
METHODS: Twelve post-therapy patients with histology proven gliomas (six grade II and six grade III) presented with magnetic resonance imaging (MRI) and clinical symptoms suggestive but not conclusive of progression were entered into the study. (1) H MRS data were acquired and 3-dimensional volumetric maps of choline (Cho) over creatine (Cr) were generated. Intensity of (18) F-FDG uptake was evaluated on a semiquantitative scale.
RESULTS: The accuracy of (1) H MRS and (18) F-FDG-PET imaging for diagnosis of glioma progression was 75% and 83%, respectively. Classifying the tumors by grade improved accuracy of (18) F-FDG-PET to 100% in high-grade gliomas and accuracy of (1) H MRS to 80% in low-grade tumors. Spearman's analysis demonstrated a trend between (18) F-FDG uptake and tumor grading (ρ= .612, P-value = .272). The results of (18) F-FDG-PET and (1) H MRS were concordant in 75% (9/12) of cases.
CONCLUSION: The combination of (1) H MRS data and (18) F-FDG-PET imaging can enhance detection of glioma progression. (1) H MRS imaging was more accurate in low-grade gliomas and (18) F-FDG-PET provided better accuracy in high-grade gliomas.
Copyright © 2010 by the American Society of Neuroimaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21155917      PMCID: PMC3135727          DOI: 10.1111/j.1552-6569.2010.00561.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  42 in total

1.  Prediction of pathology and survival by FDG PET in gliomas.

Authors:  M V Padma; S Said; M Jacobs; D R Hwang; K Dunigan; M Satter; B Christian; J Ruppert; T Bernstein; G Kraus; J C Mantil
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

2.  Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence.

Authors:  Tracy R McKnight; Mary H von dem Bussche; Daniel B Vigneron; Ying Lu; Mitchel S Berger; Michael W McDermott; William P Dillon; Edward E Graves; Andrea Pirzkall; Sarah J Nelson
Journal:  J Neurosurg       Date:  2002-10       Impact factor: 5.115

3.  Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses.

Authors:  P T Meyer; M Schreckenberger; U Spetzger; G F Meyer; O Sabri; K S Setani; T Zeggel; U Buell
Journal:  Eur J Nucl Med       Date:  2001-02

4.  The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery.

Authors:  S T Chao; J H Suh; S Raja; S Y Lee; G Barnett
Journal:  Int J Cancer       Date:  2001-06-20       Impact factor: 7.396

5.  Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume.

Authors:  J E Marks; R J Baglan; S C Prassad; W F Blank
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-02       Impact factor: 7.038

6.  [18F]-labeled 3-deoxy-3-fluoro-D-glucose: synthesis and preliminary biodistribution data.

Authors:  T J Tewson; M J Welch; M E Raichle
Journal:  J Nucl Med       Date:  1978-12       Impact factor: 10.057

7.  Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values.

Authors:  Christian Senft; Elke Hattingen; Ulrich Pilatus; Kea Franz; Anne Schänzer; Heinrich Lanfermann; Volker Seifert; Thomas Gasser
Journal:  Neurosurgery       Date:  2009-11       Impact factor: 4.654

Review 8.  The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases.

Authors:  P C Burger; M S Mahley; L Dudka; F S Vogel
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

9.  Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors.

Authors:  Sebastian Herminghaus; Ulrich Pilatus; Walter Möller-Hartmann; Peter Raab; Heinrich Lanfermann; Wolfgang Schlote; Friedhelm E Zanella
Journal:  NMR Biomed       Date:  2002-10       Impact factor: 4.044

10.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.

Authors:  Meng Law; Stanley Yang; Hao Wang; James S Babb; Glyn Johnson; Soonmee Cha; Edmond A Knopp; David Zagzag
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

View more
  12 in total

Review 1.  Brain tumors.

Authors:  Karl Herholz; Karl-Josef Langen; Christiaan Schiepers; James M Mountz
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

2.  Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors.

Authors:  Matthias Preuss; Peter Werner; Henryk Barthel; Ulf Nestler; Holger Christiansen; Franz Wolfgang Hirsch; Dominik Fritzsch; Karl-Titus Hoffmann; Matthias K Bernhard; Osama Sabri
Journal:  Childs Nerv Syst       Date:  2014-04-08       Impact factor: 1.475

3.  Grading of cerebral glioma with multiparametric MR imaging and 18F-FDG-PET: concordance and accuracy.

Authors:  Jeong Hee Yoon; Ji-hoon Kim; Won Jun Kang; Chul-Ho Sohn; Seung Hong Choi; Tae Jin Yun; Yong Eun; Yong Sub Song; Kee-Hyun Chang
Journal:  Eur Radiol       Date:  2014-02       Impact factor: 5.315

4.  Molecular imaging of pediatric brain tumors: comparison of tumor metabolism using ¹⁸F-FDG-PET and MRSI.

Authors:  Sean J Hipp; Emilie A Steffen-Smith; Nicholas Patronas; Peter Herscovitch; Jeffrey M Solomon; Robyn S Bent; Seth M Steinberg; Katherine E Warren
Journal:  J Neurooncol       Date:  2012-07-04       Impact factor: 4.130

5.  Molecular and metabolic pattern classification for detection of brain glioma progression.

Authors:  Farzin Imani; Fernando E Boada; Frank S Lieberman; Denise K Davis; James M Mountz
Journal:  Eur J Radiol       Date:  2013-11-20       Impact factor: 3.528

6.  Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.

Authors:  Giovanni Morana; Arnoldo Piccardo; Matteo Puntoni; Paolo Nozza; Armando Cama; Alessandro Raso; Samantha Mascelli; Michela Massollo; Claudia Milanaccio; Maria Luisa Garrè; Andrea Rossi
Journal:  Neuro Oncol       Date:  2015-09-23       Impact factor: 12.300

7.  IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.

Authors:  Manuel Röhrich; Anastasia Loktev; Annika K Wefers; Annette Altmann; Daniel Paech; Sebastian Adeberg; Paul Windisch; Thomas Hielscher; Paul Flechsig; Ralf Floca; Dominik Leitz; Julius P Schuster; Peter E Huber; Jürgen Debus; Andreas von Deimling; Thomas Lindner; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-06       Impact factor: 9.236

Review 8.  Functional imaging in adult and paediatric brain tumours.

Authors:  Andrew C Peet; Theodoros N Arvanitis; Martin O Leach; Adam D Waldman
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

Review 9.  Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods.

Authors:  Rafay Ahmed; Matthew J Oborski; Misun Hwang; Frank S Lieberman; James M Mountz
Journal:  Cancer Manag Res       Date:  2014-03-24       Impact factor: 3.989

Review 10.  The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Sarah Jost Fouke; Tammie Benzinger; Daniel Gibson; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.